echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hausen even reported 2 innovative drugs!

    Hausen even reported 2 innovative drugs!

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 28, the CDE official website showed that Hansen Pharmaceuticals continuously applied for two innovative drugs HS-10375 and HS-10381


    According to the Insight database, as of July 28, Hansen had 32 products in its innovative drug pipeline


    Among them, it is worth noting that in recent years, Hansen has increased its investment in research and development, and the development of innovative drugs has accelerated.


    New projects in 2021: immunity, tumor, hypoglycemic

    New projects in 2021: immunity, tumor, hypoglycemic

    Judging from the disclosed information of Hansen’s newly declared and initiated clinical innovative drug projects in 2021, its new drug layout involves multiple fields, including HS-10360, HS-10374 in the field of self-immunization, anti-tumor drug HS-10365, dual target Point the hypoglycemic drug HS-20094, and the mental field antidepressant HS-10353


    Among them, HS-20094 is worthy of attention


    Biopharmaceuticals start to work

    Biopharmaceuticals start to work

    On July 15th, Hansen Pharmaceutical successively applied for two types of Class 1 therapeutic biological products HS-20093 and HS-20089, which were accepted by CDE, which marked Hansen's start in the field of biological medicine


    The first biological drug declared by Hausen is the CD19 monoclonal antibody Inebilizumab introduced from Viela Bio, which is a first-in-class new drug for neuromyelitis optica spectrum disorder (NMOSD)


    In addition, Hansen's fastest-growing biologic drug is HS-20090, a biosimilar to Disuzumab, which started phase 1 clinical trials in September 2020


    At present, Hansen Pharmaceuticals has established a biological drug research and development center, and its products cover the fields of monoclonal antibodies, double antibodies, ADCs and fusion proteins


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.